Avadel has for years been locked in litigation with its biggest competitor in narcolepsy treatments. Photo: Rafael Henrique/SOPA Images/Reuters ASL Strategic Value Fund plans to publish an open letter arguing that Avadel has mismanaged the launch of its main treatment, causing the company to miss out on hundreds of millions of dollars in revenue, according to a copy of the letter viewed by The Wall Street Journal. An investor in the narcolepsy drugmaker Avadel Pharmaceuticals AVDL -0.97 %decrease; red down ...